HENDERSON, Nev., Jan. 4, 2024
/PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX)
("Volition"), a multi-national epigenetics company, has issued a
Business Review of 2023, outlining its key highlights from the past
year.
Volition's major achievements in 2023 include:
- Launching the Nu.Q® Vet Cancer Test in some significant
markets through several licensing, supply and/or distribution
agreements.
- Establishing several agreements to further expand access to
the Nu.Q® Vet Cancer Test on a worldwide basis in 2024.
- Driving a market access program for Nu.Q® NETs, working with
Centers of Excellence globally to exemplify its clinical
utility.
- Completing the Q-Sub process with the U.S. Food and Drug
Administration, and establishing a clear regulatory pathway for
Nu.Q® NETs.
- Announcing a breakthrough early cancer detection method.
- Continuing to strengthen our strategic patent portfolio.
- Scaling up its operations, in particular production
capacity.
To find out more about these achievements, please read
Volition's Business Review here or watch the video below.
Video - https://www.youtube.com/watch?v=YF_DAUp45Sc
Cameron Reynolds, President and
Group Chief Executive Officer, said: "At Volition, we are dedicated
to saving lives and improving outcomes for people and animals
worldwide through our novel epigenetics platform.
"We believe we made great progress in our mission throughout
2023 and have in place compelling plans to move forward in
2024."
Volition is developing simple, easy-to-use, cost-effective blood
tests to help diagnose and monitor a range of life-altering
diseases in both humans and animals. For more information about
Volition's technology go to: www.volition.com
About Volition
Volition is a multi-national epigenetics company focused on
advancing the science of epigenetics. Volition is dedicated to
saving lives and improving outcomes for people and animals with
life-altering diseases through earlier detection, as well as
disease and treatment monitoring.
Through its subsidiaries, Volition is developing and
commercializing simple, easy to use, cost-effective blood tests to
help diagnose and monitor a range of diseases, including some
cancers and diseases associated with NETosis, such as sepsis. Early
diagnosis and monitoring have the potential to not only prolong the
life of patients, but also improve their quality of life.
Volition's research and development activities are centered in
Belgium, with an innovation
laboratory and office in the U.S. and additional offices in
London and Singapore.
The contents found at Volition's website address are not
incorporated by reference into this document and should not be
considered part of this document. Such website address is
included in this document as an inactive textual reference
only.
Media Enquiries:
Louise Batchelor/Debra Daglish, Volition,
mediarelations@volition.com +44 (0)7557 774620
Safe Harbor Statement
Statements in this Business Review may be "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended, that concern matters that involve risks and
uncertainties that could cause actual results to differ materially
from those anticipated or projected in the forward-looking
statements. Words such as "expects," "anticipates," "intends,"
"plans," "aims," "targets," "believes," "seeks," "estimates,"
"optimizing," "potential," "goal," "suggests," "could," "would,"
"should," "may," "will" and similar expressions identify
forward-looking statements. These forward-looking statements relate
to, among other topics, Volition's expectations related to the
launch of product sales with Heska and other counterparties to
agreements, the success of negotiations and the timing, completion
and execution of term sheets and/or agreements with third parties
regarding the licensing and distribution of Volition's products,
the timing, completion, success and delivery of data from clinical
studies, the potential uses, benefits and effectiveness of its
Nucleosomics™ technology platform, including the Nu.Q® NETs test
and the Nu.Q® Vet Cancer Test, and the timing and execution of
Volition's strategy with the FDA. Volition's actual results
may differ materially from those indicated in these forward-looking
statements due to numerous risks and uncertainties, including,
without limitation, results of studies testing the efficacy of its
tests, a failure by the marketplace to accept Volition's Nu.Q® NETs
test, Nu.Q® Vet Cancer Test or other products based on its
Nucleosomics™ platform; Volition's failure to secure adequate
intellectual property protection; Volition's failure to obtain
necessary regulatory clearances or approvals to distribute and
market future products; Volition will face fierce competition and
its intended products may become obsolete due to the highly
competitive nature of the diagnostics and disease monitoring
markets and their rapid technological change; downturns in domestic
and foreign economies; and other risks, including those identified
in Volition's most recent Annual Report on Form 10-K and Quarterly
Reports on Form 10-Q, as well as other documents that Volition
files with the Securities and Exchange Commission. For instance, if
Volition fails to develop and commercialize diagnostic, prognostic
or disease monitoring products, it may be unable to execute its
plan of operations. Forward-looking statements are based on current
expectations, estimates and projections about Volition's business
based, in part, on assumptions made by management. These statements
are not guarantees of future performance and involve risks,
uncertainties and assumptions that are difficult to predict.
Forward-looking statements are made as of the date of this Business
Review, and, except as required by law, Volition does not undertake
an obligation to update its forward-looking statements to reflect
future events or circumstances.
Nucleosomics™ and Nu.Q® and their respective logos are
trademarks and/or service marks of VolitionRx Limited and its
subsidiaries. All other trademarks, service marks and trade names
referred to in this Business Review are the property of their
respective owners.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/volition-issues-business-review-2023-302026231.html
SOURCE VolitionRx Limited